Clinical Trials
24 trialsI-SPY
QuantumLeap Healthcare Collaborative
Capecitabine 7/7 Schedule With Neratinib in Patients With Metastatic HER2-Positive Breast Cancer
Memorial Sloan Kettering Cancer Center
Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers
Hoosier Cancer Research Network
Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer
M.D. Anderson Cancer Center
HKI-272 for HER2-Positive Breast Cancer and Brain Metastases
Dana-Farber Cancer Institute
Neratinib +/- Fulvestrant in HER2+, ER+ Metastatic Breast Cancer
Dana-Farber Cancer Institute
Trial of Neratinib Plus Capecitabine in Subjects With HER2-Negative Metastatic Breast Cancer With Brain Metastases and Abnormally Active HER2 Signaling
University of Rochester
Neratinib in Combination With Ruxolitinib in Patients With mTNBC
Baylor Research Institute
Adjuvant Trastuzumab Plus Neratinib in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Neoadjuvant Trastuzumab Plus Pertuzumab
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
THUNDER
Fudan University
Incidence and Severity of Diarrhea in Patients With HER2 Positive Breast Cancer Treated With Trastuzumab and Neratinib
University of California, San Francisco
Neratinib in Extended Adjuvant Treatment for HER2+ Early Breast Cancer With pCR But High-Risk Features: A Hebei Multi-Center Real-World Study
Hebei Medical University Fourth Hospital
Neratinib and Capmatinib Combination (Phase Ib/II) in Metastatic Breast Cancer and Inflammatory Breast Cancer Patients With Abnormal HER-family and c-Met Pathway Activity as Measured by the CELsignia Signaling Analysis Test
M.D. Anderson Cancer Center
DIANER
Spanish Breast Cancer Research Group
Kadcyla And Neratinib for Interception of HER2+ Breast Cancer With Molecular Residual Disease
University Health Network, Toronto
NeraHER2
Peking University People's Hospital
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
OHSU Knight Cancer Institute
FACT-2
West Cancer Center
HER2-Signal
Massachusetts General Hospital
Neratinib in Treating Older Patients With Stage IV HER2-Positive Breast Cancer
City of Hope Medical Center
NEREA
SOLTI Breast Cancer Research Group
Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer
Washington University School of Medicine
NeraBrain
Jules Bordet Institute
plasmaMATCH
Institute of Cancer Research, United Kingdom